Background: Current guidelines for gender-affirming hormone therapy (GAHT) for
transgender women are mostly based on clinical experience from experts in the field and …

Introduction: In the last decade, healthcare for the transgender population has increased
considerably in many countries thanks to depathologization movements and the easier …

Purpose Gender affirming hormone therapy (HT) in transgender men both improves and
impairs several surrogate cardiovascular risk markers. However, few prospective works with …

Androgen therapy is the mainstay of treatment in female to male (FtM) transgender persons
to increase testosterone levels, suppress oestrogens and treat gender dysphoria …

Aims We compared the incidence of cardiovascular disease (CVD) in transgender
participants with a diagnosis of gender dysphoria (GD) with and without gender-affirming …

OBJECTIVE: The aim of this study is to compare the risk of venous thromboembolic events
(VTE) between patients suspending and continuing estrogen therapy perioperatively, in …

Objective To review he impact of estrogen-containing feminizing hormone regimens on
transgender individuals' risk for VTE. Methods We evaluated VTE risk by screening 1170 …

Transgender men and women represent a growing population in the United States and
Europe, with 0.5% of adults and 3% of youth identifying as transgender. Globally, an …

Objective We aimed to investigate the effect of gender-affirming hormone therapy (GAHT) on
cardiovascular disease risk factors focusing on glucose tolerance. Patients and Methods …

Background: Transgender and gender nonconforming (TG) youth who are at increased risk
of thrombosis may be evaluated by a hematologist to discuss thromboprophylaxis prior to …